Literature DB >> 21773973

Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer.

Keiji Inoue1, Hideo Fukuhara, Tsutomu Shimamoto, Masayuki Kamada, Tatsuo Iiyama, Mitsuhiko Miyamura, Atsushi Kurabayashi, Mutsuo Furihata, Masanobu Tanimura, Hironobu Watanabe, Taro Shuin.   

Abstract

BACKGROUND: This study was undertaken to evaluate the clinical value of photodynamic diagnosis (PDD) with intravesical and oral instillation of 5-aminolevulinic acid (ALA) (ALA-PDD), and transurethral resection of bladder tumor (TURBT) guided by ALA-PDD (PDD-TURBT) for nonmuscle invasive bladder cancer.
METHODS: Of all 210 cases, 75 underwent PDD with intravesically applied ALA, and 135 cases underwent PDD with orally applied ALA. Diagnostic accuracy was evaluated by comparing the level on images of ALA-induced fluorescence with the pathological result. PDD-TURBT was performed in 99 completely resectable cases corresponding to 210 ALA-PDD cases. To evaluate the abilities of PDD-TURBT, survival analysis regarding intravesical recurrence was retrospectively compared with the historical control cases that underwent conventional TURBT.
RESULTS: The diagnostic accuracy and capability of ALA-PDD were significantly superior to those of conventional endoscopic examination. Moreover, 72.1% of flat lesions, including dysplasia and carcinoma in situ, could be detected only by ALA-PDD. The recurrence-free survival rate in the cases that underwent PDD-TURBT was significantly higher than that of conventional TURBT. Moreover, multivariate analysis revealed that the only independent factor contributing to improving prognosis was PDD-TURBT (hazard ratio, 0.578; P = .012). Regardless of the ALA administration route, there was no significant difference in diagnostic accuracy, ability of PDD, or recurrence-free survival. All procedures were well tolerated by all patients without any severe adverse events.
CONCLUSIONS: This multicenter study is likely to be biased, because it is limited by the retrospective analysis. This study suggests that regardless of the ALA administration route, ALA-PDD and PDD-TURBT are remarkably helpful in detection and intraoperative navigation programs.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21773973     DOI: 10.1002/cncr.26378

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  Plasma protoporphyrin IX following administration of 5-aminolevulinic acid as a potential tumor marker.

Authors:  Urara Ota; Hideo Fukuhara; Masahiro Ishizuka; Fuminori Abe; Chiaki Kawada; Kenji Tamura; Tohru Tanaka; Keiji Inoue; Shun-Ichiro Ogura; Taro Shuin
Journal:  Mol Clin Oncol       Date:  2015-04-24

Review 2.  Photodynamic diagnosis and therapy for urothelial carcinoma and prostate cancer: new imaging technology and therapy.

Authors:  Hideo Fukuhara; Shinkuro Yamamoto; Takashi Karashima; Keiji Inoue
Journal:  Int J Clin Oncol       Date:  2020-05-26       Impact factor: 3.402

3.  Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection.

Authors:  Kyle I Swanson; Paul A Clark; Ray R Zhang; Irawati K Kandela; Mohammed Farhoud; Jamey P Weichert; John S Kuo
Journal:  Neurosurgery       Date:  2015-02       Impact factor: 4.654

4.  Significance of 5-Aminolevulinic Acid-mediated Photodynamic Diagnosis Following Standard Transurethral Resection in Non-muscle Invasive Bladder Cancer.

Authors:  Kyohei Watanabe; Keita Tamura; Yuto Matsushita; Hiromitsu Watanabe; Daisuke Motoyama; Toshiki Ito; Takayuki Sugiyama; Atsushi Otsuka; Hideaki Miyake
Journal:  Cancer Diagn Progn       Date:  2021-07-03

Review 5.  Clinical applications of 5-aminolevulinic acid-mediated fluorescence for gastric cancer.

Authors:  Tsutomu Namikawa; Tomoaki Yatabe; Keiji Inoue; Taro Shuin; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

Review 6.  Clinical application of photodynamic medicine technology using light-emitting fluorescence imaging based on a specialized luminous source.

Authors:  Tsutomu Namikawa; Kazune Fujisawa; Eri Munekage; Jun Iwabu; Sunao Uemura; Shigehiro Tsujii; Hiromichi Maeda; Hiroyuki Kitagawa; Hideo Fukuhara; Keiji Inoue; Takayuki Sato; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Med Mol Morphol       Date:  2018-04-04       Impact factor: 2.309

7.  Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy.

Authors:  Kentaro Kishi; Yoshiyuki Fujiwara; Masahiko Yano; Masaaki Motoori; Keijiro Sugimura; Hidenori Takahashi; Masayuki Ohue; Masato Sakon
Journal:  Surg Today       Date:  2016-03-23       Impact factor: 2.549

8.  Initial experience of combined use of photodynamic diagnosis and narrow band imaging for detection of flat urothelial lesion.

Authors:  Yoshio Naya; Masakastu Oishi; Yasunori Yamada; Takashi Ueda; Atsuko Fujihara; Hiroyuki Nakanishi; Yasuyuki Naito; Terukazu Nakamura; Fumiya Hongo; Kazumi Kamoi; Koji Okihara; Tsuneharu Miki
Journal:  Int J Clin Oncol       Date:  2014-09-18       Impact factor: 3.402

9.  Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.

Authors:  Tzu-Yin Lin; Yuanpei Li; Qiangqiang Liu; Jui-Lin Chen; Hongyong Zhang; Diana Lac; Hua Zhang; Katherine W Ferrara; Sebastian Wachsmann-Hogiu; Tianhong Li; Susan Airhart; Ralph deVere White; Kit S Lam; Chong-Xian Pan
Journal:  Biomaterials       Date:  2016-07-22       Impact factor: 12.479

10.  Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation.

Authors:  Hirotsugu Kobuchi; Koko Moriya; Tetsuya Ogino; Hirofumi Fujita; Keiji Inoue; Taro Shuin; Tatsuji Yasuda; Kozo Utsumi; Toshihiko Utsumi
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.